Status:
TERMINATED
Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy
Lead Sponsor:
Drexel University
Conditions:
Epilepsy
Magnesium Deficiency
Eligibility:
All Genders
18-70 years
Brief Summary
The objective of this study is to determine the role of magnesium on bone and vitamin D metabolism in patients receiving anti-epileptic medications.
Eligibility Criteria
Inclusion
- Individuals receiving anti-epileptic drugs as a treatment for epilepsy
Exclusion
- Individuals who are pregnant or breastfeeding, receiving cancer treatments, have liver or kidney diseases, autoimmune diseases, or other diseases that may interfere with vitamin D and magnesium metabolism.
Key Trial Info
Start Date :
August 10 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2019
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT03471481
Start Date
August 10 2015
End Date
August 1 2019
Last Update
March 1 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Drexel University Nutrition Sciences Research Lab
Philadelphia, Pennsylvania, United States, 19102
2
Drexel University
Philadelphia, Pennsylvania, United States, 19102